"Bevacizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF RECEPTORS and helps prevent the proliferation of blood vessels.
| Descriptor ID |
D000068258
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.375 D12.776.124.790.651.114.224.060.438 D12.776.377.715.548.114.224.200.438
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bevacizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Bevacizumab [D12.776.124.486.485.114.224.060.375]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Bevacizumab [D12.776.124.790.651.114.224.060.438]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Bevacizumab [D12.776.377.715.548.114.224.200.438]
Below are MeSH descriptors whose meaning is more specific than "Bevacizumab".
This graph shows the total number of publications written about "Bevacizumab" by people in this website by year, and whether "Bevacizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 9 | 9 |
| 2009 | 0 | 7 | 7 |
| 2010 | 0 | 17 | 17 |
| 2011 | 0 | 16 | 16 |
| 2012 | 0 | 20 | 20 |
| 2013 | 0 | 12 | 12 |
| 2014 | 0 | 13 | 13 |
| 2015 | 1 | 4 | 5 |
| 2016 | 5 | 5 | 10 |
| 2017 | 3 | 2 | 5 |
| 2018 | 2 | 5 | 7 |
| 2019 | 8 | 4 | 12 |
| 2020 | 2 | 6 | 8 |
| 2021 | 2 | 8 | 10 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 5 | 5 |
| 2024 | 5 | 4 | 9 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bevacizumab" by people in Profiles.
-
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance). Eur J Cancer. 2025 Sep 09; 227:115694.
-
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. N Engl J Med. 2025 Jun 19; 392(23):2346-2356.
-
Increased Hemorrhage During Excision of Bevacizumab-Treated NF2-Related Vestibular Schwannomas. Laryngoscope. 2025 Nov; 135(11):4355-4363.
-
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104. J Neurooncol. 2025 Jul; 173(3):751-757.
-
Clinical Characteristics and Treatment Outcomes in Unilateral Coats Disease: A Global Collaborative Study. Ophthalmol Retina. 2025 Jun; 9(6):570-579.
-
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction. JAMA Oncol. 2024 Sep 01; 10(9):1253-1258.
-
Bevacizumab for Retinopathy of Prematurity Is Not Associated With Systemic Hypertension. J Pediatr Ophthalmol Strabismus. 2024 Nov-Dec; 61(6):434-441.
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
-
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment. Hepatology. 2025 Mar 01; 81(3):837-852.
-
Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatol Commun. 2024 06 01; 8(6).